Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Human Dot1L (aa 1324-1407) Control Fragment Recombinant Protein
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Product Details
RP-109446
Species
Expression System
Amino acid sequence
Tag
Class
Type
Purity
Conjugate
Form
Concentration
Purification
Storage buffer
Contains
Storage conditions
Shipping conditions
Product Specific Information
Highest antigen sequence indentity to the following orthologs: Mouse (67%), Rat (67%).
This recombinant protein control fragment may be used for blocking experiments. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Target Information
DOT1-like histone lysine methyltransferase (DOT1L) is a gene located on chromosome 19q13.12, encoding an enzyme responsible for methylating lysine 79 on histone H3, a critical modification influencing chromatin structure and gene expression. Unlike most histone methyltransferases, DOT1L does not contain a SET domain and uniquely catalyzes H3K79 methylation, which plays pivotal roles in the regulation of transcription and maintenance of genomic stability. Expression of DOT1L is vital for various biological processes, including cell cycle progression, development, and differentiation, particularly in hematopoietic cells. Aberrations in DOT1L activity have been associated with mixed-lineage leukemia (MLL), where DOT1L-mediated H3K79 methylation contributes to leukemogenesis by influencing gene expression related to proliferation and survival. Due to its involvement in cancer progression, DOT1L is being investigated as a therapeutic target, with inhibitors developed to specifically modulate its enzymatic activity, offering potential for treating MLL and other malignancies.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Bioinformatics
Protein Aliases: DKFZp586P1823; DOT1 like histone H3K79 methyltransferase; DOT1-like histone H3K79 methyltransferase; DOT1-like protein; DOT1-like, histone H3 methyltransferase; H3-K79-HMTase; Histone H3-K79 methyltransferase; histone methyltransferase DOT1L; Histone-lysine N-methyltransferase, H3 lysine-79 specific; Lysine N-methyltransferase 4
Gene Aliases: DOT1; DOT1L; KIAA1814; KMT4
UniProt ID: (Human) Q8TEK3
Entrez Gene ID: (Human) 84444
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support